Drugs / 9MW1911
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05803902 | Dec 2021 → Mar 2023 | asthma, atopic eczema, chronic obstructive pulmonary disease | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06175351 | Jul 2023 → Sep 2025 overdue | chronic obstructive pulmonary disease | Mabwell (Shanghai) Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07292714 | Jul 2025 → Dec 2027 expected | chronic obstructive pulmonary disease | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05170243 Comparator | Jan → Jul 2022 | asthma, atopic eczema, chronic obstructive pulmonary disease | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW1911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07292714 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT05170243 ↗ |